Exhibit 99.1 Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update FDA lifts partial clinical holds on ersodetug for the treatment of congenital HI; Phase 3 sunRIZE study to proceed in the U.S. Phase 3 study for ersodetug for the treatment of tumor HI expected to commence in the first half of 2025 REDWOOD CITY, Calif., September 19, 2024 – Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a latestage biopharmaceutical company dedicated todevelopi ...